-+ 0.00%
-+ 0.00%
-+ 0.00%

CADRENAL THERAPEUTICS ACQUIRES VLX-1005, A FIRST-IN-CLASS PHASE 2 12-LOX INHIBITOR FOR PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)

Reuters·12/11/2025 13:05:00

Please log in to view news